In turnabout, NICE recommends Lilly's Alimta; Sanofi, generics makers settle Eloxatin dispute;

  @FiercePharma: Abbott's White makes list of world's top CEOs. Article | Follow @FiercePharma

> Bad bottles, labels, drive two more Tylenol recalls. Report

> Eli Lilly's lung cancer drug Alimta has been recommended for use on Britain's state health service as a maintenance treatment, after a change of heart by the national health cost board. Report

> Sanofi-Aventis has settled a patent lawsuit over cancer drug Eloxatin, putting a block on several other drugmakers selling their generic versions from late June until August 2012. Report

> Richard Henriques, who has been SVP of finance and corporate controller at Merck since 2006, is set to be the new CFO at the Bill & Melinda Gates Foundation. Report

> Two generic pharmaceutical manufacturers--Apotex and Roxane Laboratories--have challenged the FDA's decision to give rival Teva Pharmaceutical Industries six months of exclusive marketing for generic versions of widely-used blood pressure medicines. Report

> Purely price-based attempts to control drug spending put all healthcare players at risk, and "enforced and unpredicted" price cuts can cause serious damage, a new report warns European Union governments. Report

> Roche is seeking to broaden use of its cancer drug Rituxan in non-Hodgkin's lymphoma in the U.S., coming hot on the heels of its bid to expand use of the drug in Europe. Report

> A jury in the first federal civil trial involving a biotech worker who claims to have been injured on the job spent about two hours in deliberations Wednesday at U.S. District Court before retiring for the day without reaching a verdict. Earlier in the day, attorneys for Pfizer and former company scientist Becky McClain of Deep River clashed over the importance of the pharmaceutical giant's decision to vent possibly contaminated air into the atmosphere near its Groton research center. Story

> GlaxoSmithKline's Avodart, shown in a study to reduce the detection of prostate cancer, may give men "a false sense of security," according to an editorial in the New England Journal of Medicine. Report

> Haifa-based pharmaceuticals company Taro Pharmaceutical Industries Ltd.  has given its shareholders a Passover holiday gift, in the shape of financial statements for 2004 to 2006. This is not a mistake; we may be in 2010, but only now is Taro providing its results for those years. Report

> Albertans will pay less for existing generic drugs as part of the next phase of the provincial government's pharmaceutical strategy. Article

Biotech News

 @FierceBiotech:  Biotech inspired $295B in M&A deals over the last decade. Article | Follow @FierceBiotech

 @JohnCFierce: Cautionary tale, ARQL conference call: Analyst raises recent lung cancer failures in Ph3 for Novelos and Antisoma. Tricky field. | Follow @JohnCFierce

> MDRNA forges $46M merger pact with Cequent. Story

> Ardea shares surge on promising PhIIb gout drug data. Item

> Horizon closing in on deal to buy Nitec Pharma. Report

> Cubist shelves ecallantide program. Article

> Two of biotechnology's highest-profile CEOs--one on the way out of his job and the other enduring troubled times--took a moment to reflect on the industry's future in light of the new healthcare reform measure. And they highlighted some starkly contrasting views. Item

Manufacturing News

> My Job: Director for manufacturing compliance at CIS. Interview

> A new tool aims to simplify melamine detection in at-risk components. Story

> The persistent seizure of Indian generics at European ports may be a terminology issue. A representative from India, speaking at a World Health Organization meeting, suggests that port authorities may be confusing the terms "counterfeit" and "generic." Story

Vaccines News

> H1N1 vaccine is largely unused, almost expired. Story

> Dendreon tripling workforce ahead of expected vaccine launch. Report

> Sanofi blueprints major vaccine production expansion. Item

> Global vaccine efforts seek $24 billion in bad economic times. Article

And Finally... Changes are urgently needed to end the secrecy surrounding approval of new drugs in Europe, argue experts online in the British Medical JournalReport